Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With
Emma R Lyons1,2, Tim Vigers2, Marisa Simoni3
1Children's Hospital Colorado, Aurora, Colorado, USA.
Introduction:
Adolescents and young adults with CF (AYAwCF) are at increased risk of body image concerns due to a historical focus on weight gain, BMI, and adequate nutrition. Societal ideals create even greater risk. Elexacaftor/tezacaftor/ivacaftor (ETI) dramatically improved outcomes in CF, including contributing to weight gain. To date, no research has examined body image and adherence to ETI in AYAwCF. This study examines perspectives of AYAwCF on how body image may relate to ETI adherence.
Methods:
Participants (n = 52) who were prescribed ETI for at least 6 months completed a series of questionnaires assessing: (1) body image concerns; (2) self-reported adherence to ETI; (3) perceptions related to ETI. Medical outcomes (body mass index [BMI], forced expiratory volume in 1 s [FEV1]), demographic information, and mental health screening data were collected via retrospective chart review.
Results:
AYAwCF's perceptions of ETI adherence significantly differed based on body dissatisfaction; those with body dissatisfaction were more likely to endorse their weight and/or body image as a factor impacting ETI adherence, and those who wanted to be smaller were more likely to not want to take ETI due to weight gain. Differences between gender and body dissatisfaction emerged, showing that females more frequently reported wanting a smaller body. Among AYAwCF with elevated anxiety, those with body dissatisfaction had higher levels of anxiety than those without body dissatisfaction. AYAwCF with lower body esteem were more likely to have elevated symptoms of both depression and anxiety.
Discussion:
This cross-sectional, single-site study explored the relationship between body image concerns for AYAwCF since the approval of ETI and their relationship to adherence. Results help identify areas for intervention.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Drug Dosing: Obese Patients
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Urologic Endoscopic Procedure: Cystoscopic Examination
